‘Wait-and-See Time’: Panel Predicts Limited Congressional Action On Devices This Year
An expert panel at the FDLI annual meeting expects the US Congress to want to see more results from recent legislation on devices before it moves ahead with further FDA reform. Though, pandemic-related measures remain a priority.
You may also be interested in...
FDA Encourages Voluntary Device Shortage Reporting After PHE End
The FDA updated its policies regarding 506J notifications for device manufacturers at the end of the public health emergency.
‘We Need More Time‘: Medtech Groups Testify Before EPA On ETO Emissions Regulation
Medtech groups call for extended commentary and compliance periods for two new EtO regulations from the EPA.
What Should Be Included In PAHPA's Reauthorization?
At the first meeting of the Capitol Hill steering committee on pandemic preparedness, experts weighed in on what they hope to see in PAHPA’s reauthorization.